Targeting cancer with phosphodiesterase inhibitors

Expert Opinion on Investigational Drugs

Volumn 19, Issue 1, 2010, Pages 117-131

  Savai, Rajkumar ^a   Pullamsetti, Soni Savai ^b   Banat, Gamal Andre ^a   Weissmann, Norbert ^a   Ghofrani, Hossein Ardeschir ^a   Grimminger, Friedrich ^a   Schermuly, Ralph Theo ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

CAMP; CGMP; Cyclic nucleotides; PDE inhibitors; Phosphodiesterases; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CILOMILAST; CILOSTAZOL; CP 461; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC GMP; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPYRIDAMOLE; DOCETAXEL; ERLOTINIB; FORSKOLIN; ISOENZYME; METHYLXANTHINE; MILRINONE; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; ROFLUMILAST; ROLIPRAM; SILDENAFIL; SULINDAC SULFONE; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER GROWTH; CANCER THERAPY; CELL CYCLE ARREST; CELL GROWTH; CLINICAL TRIAL; CRYSTAL STRUCTURE; DIMERIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; FOLLICULAR LYMPHOMA; GENE OVEREXPRESSION; HUMAN; LARGE CELL LYMPHOMA; LUNG CANCER; MICROENVIRONMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 72049100184     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903485642     Document Type: Review

References (139)

1. Vainio H, Moller H. Mechanisms of carcinogenesis and molecular epidemiology. Eur J Cancer 1993;29A:1226-1227
2. Bertram JS. The molecular biology of cancer. Mol Aspects Med 2000;21:167-223
3. Rubin H. What keeps cells in tissues behaving normally in the face of myriad mutations? Bioessays 2006;28:515-524
4. Stanley LA. Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. Toxicology 1995;96:173-194
5. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336
6. Simon MM, Sliutz G, Luger TA. Proto-oncogenes and oncogenes in epidermal neoplasia. Exp Dermatol 1995;4:65-73
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
8. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-341
9. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995;14:6209-6217
10. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432:635-639
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
12. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572
13. Wyatt RM, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol 2008;81:549-563
14. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-729
15. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006;296:1518-1520
16. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction: a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3:448-457
17. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006;62:15-26 (Pubitemid 44195239)
18. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006;31:680-686
19. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004;84:137-167
20. Schaub MC, Hefti MA, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol 2006;41:183-214
21. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 2005;579:3264-3270
22. Zhang L, Murray F, Zahno A, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2008;105:19532-19537
23. Marko D, Romanakis K, Zankl H, et al. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem Biophys 1998;28:75-101
24. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 1990;50:7093-7100
25. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann NY Acad Sci 2005;1058:76-86
26. McDaid HM, Cairns MT, Atkinson RJ, et al. Increased expression of the RI-alpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer 1999;79:933-939
27. Cheadle C, Nesterova M, Watkins T, et al. Regulatory subunits of PKA define an axis of cellular proliferation/differentiation in ovarian cancer cells. BMC Med Genomics 2008;1:43
28. Lange-Carter CA, Fossli T, Jahnsen T, Malkinson AM. Decreased expression of the type I isozyme of cAMP-dependent protein kinase in tumor cell lines of lung epithelial origin. J Biol Chem 1990;265:7814-7818
29. Lange-Carter CA, Malkinson AM. Alterations in the cAMP signal transduction pathway in mouse lung tumorigenesis. Exp Lung Res 1991;17:341-357
30. Wong AS, Kim SO, Leung PC, et al. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 2001;82:305-311
31. Frattola L, Tonini C, Villani R, Trabucchi M. Basal, cAMP-and cGMP-dependent protein kinases in human brain tumors. Acta Neurol Scand 1979;60:344-351
32. Hou Y, Gupta N, Schoenlein P, et al. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett 2006;240:60-68 (Pubitemid 44037177)
33. Yamanaka Y, Mammoto T, Kirita T, et al. Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP. Cancer Lett 2002;176:143-148
34. Timoshenko AV, Xu G, Chakrabarti S, et al. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265-274
35. Murata K, Kameyama M, Fukui F, et al. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility. Clin Exp Metastasis 1999;17:525-530
36. McEwan DG, Brunton VG, Baillie GS, et al. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res 2007;67:5248-5257
37. Al-Wadei HA, Schuller HM. Cyclic adenosine monophosphate-dependent cell type-specific modulation of mitogenic signaling by retinoids in normal and neoplastic lung cells. Cancer Detect Prev 2006;30:403-411
38. Huston E, Lynch MJ, Mohamed A, et al. EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc Natl Acad Sci USA 2008;105:12791-12796
39. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-5362
40. Shailubhai K, Yu HH, Karunanandaa K, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 2000;60:5151-5157
41. Pitari GM, Di Guglielmo MD, Park J, et al. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA 2001;98:7846-7851
42. Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 2004;64:3966-3973
43. Wu F, Wu Q. Corin-mediated processing of pro-atrial natriuretic peptide in human small cell lung cancer cells. Cancer Res 2003;63:8318-8322
44. Liu L, Li H, Underwood T, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther 2001;299:583-592
45. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569-1578
46. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000;12:174-179
47. Naviglio S, Caraglia M, Abbruzzese A, et al. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 2009;13:83-92
48. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-1519
49. Fan CK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006;533:110-117
50. Oki N, Takahashi SI, Hidaka H, Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J Biol Chem 2000;275:10831-10837
51. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007;100:309-327
52. Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999;63:1-38
53. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005;175:1523-1531
54. Lynch MJ, Baillie GS, Mohamed A, et al. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 2005;280:33178-33189
55. Wang H, Peng MS, Chen Y, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 2007;408:193-201
56. Ke H, Wang H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 2007;7:391-403
57. Mackenzie SJ, Baillie GS, McPhee I, et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 2002;136:421-433
58. Hoffmann R, Baillie GS, Mackenzie SJ, et al. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 1999;18:893-903
59. Heikaus CC, Stout JR, Sekharan MR, et al. Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem 2008;283:22749-22759
60. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-398
61. Hoffmann R, Wilkinson IR, McCallum JF, et al. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 1998;333 (Pt 1):139-149
62. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 1996;271:16526-16534
63. Mackenzie SJ, Baillie GS, McPhee I, et al. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 2000;275:16609-16617
64. McCahill A, McSorley T, Huston E, et al. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 2005;17:1158-1173
65. Favot L, Keravis T, Lugnier C. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 2004;92:634-645
66. Loughney K, Martins TJ, Harris EA, et al. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3¢,5¢-cyclic nucleotide phosphodiesterases. J Biol Chem 1996;271:796-806
67. Bender AT, Ostenson CL, Wang EH, Beavo JA. Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. Proc Natl Acad Sci USA 2005;102:497-502
68. Suttorp N, Weber U, Welsch T, Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 1993;91:1421-1428
69. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76:481-511
70. Feijge MA, Ansink K, Vanschoonbeek K, Heemskerk JW. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem Pharmacol 2004;67:1559-1567
71. Leroy MJ, Degerman E, Taira M, et al. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 1996;35:10194-10202
72. Taira M, Hockman SC, Calvo JC, et al. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 1993;268:18573-18579
73. Aizawa T, Wei H, Miano JM, et al. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003;93:406-413
74. Bolger G, Michaeli T, Martins T, et al. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 1993;13:6558-6571
75. Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003;278:5493-5496
76. Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007;100:950-966
77. Mehats C, Jin SL, Wahlstrom J, et al. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 2003;17:1831-1841
78. Ariga M, Neitzert B, Nakae S, et al. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 2004;173:7531-7538
79. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-175
80. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991;46:512-523
81. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
82. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694
83. Giordano D, De Stefano ME, Citro G, et al. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 2001;1539:16-27
84. Hanson KA, Ziegler JW, Rybalkin SD, et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 1998;275:L931-41
85. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003;167:1139-1141 (Pubitemid 36459662)
86. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45
87. Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 2000;271:575-583
88. Reyes-Irisarri E, Perez-Torres S, Mengod G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005;132:1173-1185
89. Dong H, Osmanova V, Epstein PM, Brocke S. Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem Biophys Res Commun 2006;345:713-719
90. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998;273:15553-15558
91. Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004;123:967-981
92. Butcher RW, Sutherland EW. Adenosine 3¢,5¢-phosphate in biological materials. I. Purification and properties of cyclic 3¢,5¢-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3¢,5¢-phosphate in human urine. J Biol Chem 1962;237:1244-1250
93. Seybold J, Thomas D, Witzenrath M, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 2005;105:3569-3576
94. Cruickshank JM. Phosphodiesterase III inhibitors: long-term risks and short-term benefits. Cardiovasc Drugs Ther 1993;7:655-660
95. Dobesh PP, Stacy ZA, Persson EL. Pharmacologic therapy for intermittent claudication. Pharmacotherapy 2009;29:526-553
96. Kambayashi J, Liu Y, Sun B, et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289-2302
97. Reilly MP, Mohler ER III. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56
98. van SE, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116:292-298
99. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161
100. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001;108:530-536
101. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-1538
102. Zeller E, Stief HJ, Pflug B, Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984;17:188-190
103. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006;147:(Suppl 1):S252-7
104. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:689-702
105. Guazzi M, Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007;14:2181-2191
106. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475
107. Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991;40:127-129
108. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008;155:308-315
109. Billington CK, Le Jeune IR, Young KW, Hall IP. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2008;38:1-7
110. Kwak HJ, Park KM, Choi HE, et al. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal 2008;20:803-814
111. Peter D, Jin SL, Conti M, et al. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007;178:4820-4831
112. Hirsh L, Dantes A, Suh BS, et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 2004;68:981-988
113. Jiang X, Paskind M, Weltzien R, Epstein PM. Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. Cell Biochem Biophys 1998;28:135-160
114. Marko D, Pahlke G, Merz KH, Eisenbrand G. Cyclic 3¢,5¢- nucleotide phosphodiesterases: potential targets for anticancer therapy. Chem Res Toxicol 2000;13:944-948
115. Zhao AZ, Yan C, Sonnenburg WK, Beavo JA. Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions. Adv Second Messenger Phosphoprotein Res 1997;31:237-251
116. Shimizu K, Murata T, Watanabe Y, et al. Characterization of phosphodiesterase 1 in human malignant melanoma cell lines. Anticancer Res 2009;29:1119-1122
117. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 2005;67:263-272
118. Favot L, Keravis T, Holl V, et al. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 2003;90:334-343
119. Murata T, Shimizu K, Narita M, et al. Characterization of phosphodiesterase 3 in human malignant melanoma cell line. Anticancer Res 2002;22:3171-3174
120. Baillie GS, Huston E, Scotland G, et al. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 2002;277:28298-28309
121. Goldhoff P, Warrington NM, Limbrick DD Jr, et al. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res 2008;14:7717-7725
122. Drees M, Zimmermann R, Eisenbrand G. 3¢,5¢-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 1993;53:3058-3061
123. Mouratidis PX, Colston KW, Bartlett JB, et al. Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells. Pancreas 2009;38:78-84
124. Fleming YM, Frame MC, Houslay MD. PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci 2004;117:2377-2388
125. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 2006;393:21-41
126. Meyers JA, Su DW, Lerner A. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol 2009;182:5400-5411
127. Ogawa R, Streiff MB, Bugayenko A, Kato GJ. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 2002;99:3390-3397
128. Siegmund B, Welsch J, Loher F, et al. Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. Leukemia 2001;15:1564-1571
129. Tiwari S, Dong H, Kim EJ, et al. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 2005;69:473-483
130. Tiwari S, Felekkis K, Moon EY, et al. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood 2004;103:2661-2667
131. Narita M, Murata T, Shimizu K, et al. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. Oncol Rep 2007;17:1133-1139
132. Piazza GA, Thompson WJ, Pamukcu R, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001;61:3961-3968
133. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 2005;94:336-350 (Pubitemid 41420312)
134. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-2702
135. Black KL, Yin D, Ong JM, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008;1230:290-302
136. Whitehead CM, Earle KA, Fetter J, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-488
137. Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002;62:5711-5719
138. D'Andrea MR, Qiu Y, Haynes-Johnson D, et al. Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 2005;53:895-903
139. Libe R, Fratticci A, Coste J, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008;14:4016-4024